173 related articles for article (PubMed ID: 38315170)
1. Polycomb repressor complex 2 suppresses interferon-responsive MHC-II expression in melanoma cells and is associated with anti-PD-1 resistance.
James JL; Taylor BC; Axelrod ML; Sun X; Guerin LN; Gonzalez-Ericsson PI; Wang Y; Sanchez V; Fahey CC; Sanders ME; Xu Y; Hodges E; Johnson DB; Balko JM
J Immunother Cancer; 2023 Nov; 11(11):. PubMed ID: 38315170
[TBL] [Abstract][Full Text] [Related]
2. Dynamic Tumor-Specific MHC-II Immuno-PET Predicts the Efficacy of Checkpoint Inhibitor Immunotherapy in Melanoma.
Yang Z; Li F; Huang Y; Yin N; Chu J; Ma Y; Pettigrew RI; Hamilton DJ; Martin DR; Li Z
J Nucl Med; 2022 Nov; 63(11):1708-1714. PubMed ID: 35210298
[TBL] [Abstract][Full Text] [Related]
3. MHC Class II is Induced by IFNγ and Follows Three Distinct Patterns of Expression in Colorectal Cancer Organoids.
Pickles OJ; Wanigasooriya K; Ptasinska A; Patel AJ; Robbins HL; Bryer C; Whalley CM; Tee L; Lal N; Pinna CMA; Elzefzafy N; Taniere P; Beggs AD; Middleton GM
Cancer Res Commun; 2023 Aug; 3(8):1501-1513. PubMed ID: 37565053
[TBL] [Abstract][Full Text] [Related]
4. EZH2: an emerging role in melanoma biology and strategies for targeted therapy.
Tiffen J; Gallagher SJ; Hersey P
Pigment Cell Melanoma Res; 2015 Jan; 28(1):21-30. PubMed ID: 24912396
[TBL] [Abstract][Full Text] [Related]
5. Polycomb recruitment at the Class II transactivator gene.
Boyd NH; Morgan JE; Greer SF
Mol Immunol; 2015 Oct; 67(2 Pt B):482-91. PubMed ID: 26283540
[TBL] [Abstract][Full Text] [Related]
6. The Histone Methyltransferase Ezh2 Controls Mechanisms of Adaptive Resistance to Tumor Immunotherapy.
Zingg D; Arenas-Ramirez N; Sahin D; Rosalia RA; Antunes AT; Haeusel J; Sommer L; Boyman O
Cell Rep; 2017 Jul; 20(4):854-867. PubMed ID: 28746871
[TBL] [Abstract][Full Text] [Related]
7. MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma.
Rodig SJ; Gusenleitner D; Jackson DG; Gjini E; Giobbie-Hurder A; Jin C; Chang H; Lovitch SB; Horak C; Weber JS; Weirather JL; Wolchok JD; Postow MA; Pavlick AC; Chesney J; Hodi FS
Sci Transl Med; 2018 Jul; 10(450):. PubMed ID: 30021886
[TBL] [Abstract][Full Text] [Related]
8. Tumor-targeted interleukin-12 synergizes with entinostat to overcome PD-1/PD-L1 blockade-resistant tumors harboring MHC-I and APM deficiencies.
Minnar CM; Chariou PL; Horn LA; Hicks KC; Palena C; Schlom J; Gameiro SR
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35764364
[TBL] [Abstract][Full Text] [Related]
9. EZH2 Cooperates with DNA Methylation to Downregulate Key Tumor Suppressors and IFN Gene Signatures in Melanoma.
Tiffen J; Gallagher SJ; Filipp F; Gunatilake D; Emran AA; Cullinane C; Dutton-Register K; Aoude L; Hayward N; Chatterjee A; Rodger EJ; Eccles MR; Hersey P
J Invest Dermatol; 2020 Dec; 140(12):2442-2454.e5. PubMed ID: 32360600
[TBL] [Abstract][Full Text] [Related]
10. Epigenetic strategies synergize with PD-L1/PD-1 targeted cancer immunotherapies to enhance antitumor responses.
Chen X; Pan X; Zhang W; Guo H; Cheng S; He Q; Yang B; Ding L
Acta Pharm Sin B; 2020 May; 10(5):723-733. PubMed ID: 32528824
[TBL] [Abstract][Full Text] [Related]
11. Interferon (IFN) beta acts downstream of IFN-gamma-induced class II transactivator messenger RNA accumulation to block major histocompatibility complex class II gene expression and requires the 48-kD DNA-binding protein, ISGF3-gamma.
Lu HT; Riley JL; Babcock GT; Huston M; Stark GR; Boss JM; Ransohoff RM
J Exp Med; 1995 Nov; 182(5):1517-25. PubMed ID: 7595221
[TBL] [Abstract][Full Text] [Related]
12. Prognostic and predictive value of PD-L2 DNA methylation and mRNA expression in melanoma.
Hoffmann F; Zarbl R; Niebel D; Sirokay J; Fröhlich A; Posch C; Holderried TAW; Brossart P; Saavedra G; Kuster P; Strieth S; Gielen GH; Ring SS; Dietrich J; Pietsch T; Flatz L; Kristiansen G; Landsberg J; Dietrich D
Clin Epigenetics; 2020 Jun; 12(1):94. PubMed ID: 32586358
[TBL] [Abstract][Full Text] [Related]
13. Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy.
Johnson DB; Estrada MV; Salgado R; Sanchez V; Doxie DB; Opalenik SR; Vilgelm AE; Feld E; Johnson AS; Greenplate AR; Sanders ME; Lovly CM; Frederick DT; Kelley MC; Richmond A; Irish JM; Shyr Y; Sullivan RJ; Puzanov I; Sosman JA; Balko JM
Nat Commun; 2016 Jan; 7():10582. PubMed ID: 26822383
[TBL] [Abstract][Full Text] [Related]
14. Epigenetic silencing of the CIITA gene and posttranscriptional regulation of class II MHC genes in ocular melanoma cells.
Radosevich M; Song Z; Gorga JC; Ksander B; Ono SJ
Invest Ophthalmol Vis Sci; 2004 Sep; 45(9):3185-95. PubMed ID: 15326139
[TBL] [Abstract][Full Text] [Related]
15. Targeting activating mutations of EZH2 leads to potent cell growth inhibition in human melanoma by derepression of tumor suppressor genes.
Tiffen JC; Gunatilake D; Gallagher SJ; Gowrishankar K; Heinemann A; Cullinane C; Dutton-Regester K; Pupo GM; Strbenac D; Yang JY; Madore J; Mann GJ; Hayward NK; McArthur GA; Filipp FV; Hersey P
Oncotarget; 2015 Sep; 6(29):27023-36. PubMed ID: 26304929
[TBL] [Abstract][Full Text] [Related]
16. A role for EZH2 in silencing of IFN-gamma inducible MHC2TA transcription in uveal melanoma.
Holling TM; Bergevoet MW; Wilson L; Van Eggermond MC; Schooten E; Steenbergen RD; Snijders PJ; Jager MJ; Van den Elsen PJ
J Immunol; 2007 Oct; 179(8):5317-25. PubMed ID: 17911618
[TBL] [Abstract][Full Text] [Related]
17. Patterns of constitutive and IFN-gamma inducible expression of HLA class II molecules in human melanoma cell lines.
Rodríguez T; Méndez R; Del Campo A; Aptsiauri N; Martín J; Orozco G; Pawelec G; Schadendorf D; Ruiz-Cabello F; Garrido F
Immunogenetics; 2007 Feb; 59(2):123-33. PubMed ID: 17180681
[TBL] [Abstract][Full Text] [Related]
18. EZH2 negatively regulates PD-L1 expression in hepatocellular carcinoma.
Xiao G; Jin LL; Liu CQ; Wang YC; Meng YM; Zhou ZG; Chen J; Yu XJ; Zhang YJ; Xu J; Zheng L
J Immunother Cancer; 2019 Nov; 7(1):300. PubMed ID: 31727135
[TBL] [Abstract][Full Text] [Related]
19. EZH2-dependent suppression of a cellular senescence phenotype in melanoma cells by inhibition of p21/CDKN1A expression.
Fan T; Jiang S; Chung N; Alikhan A; Ni C; Lee CC; Hornyak TJ
Mol Cancer Res; 2011 Apr; 9(4):418-29. PubMed ID: 21383005
[TBL] [Abstract][Full Text] [Related]
20. Melanoma response to anti-PD-L1 immunotherapy requires JAK1 signaling, but not JAK2.
Luo N; Formisano L; Gonzalez-Ericsson PI; Sanchez V; Dean PT; Opalenik SR; Sanders ME; Cook RS; Arteaga CL; Johnson DB; Balko JM
Oncoimmunology; 2018; 7(6):e1438106. PubMed ID: 29872580
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]